

Aggressive Fund

Portfolio Investment Entity

Monthly Fact Sheet as at 31 August 2023



Portfolio Managers



Stephen Johnston
Portfolio Manager



Jonathan Windust
Co-Portfolio Manager

The Fund fell 2.0% in August. Global share markets were under pressure this month, driven by bond yields moving higher. Ten-year US treasuries hit 4.34%, the highest since the Global Financial Crisis. China was another area of concern, as weakness in the Chinese property market impacted consumer confidence and had a knock-on effect to economic growth.

The top contributor this month was US insurance broker Arthur J. Gallagher (+7.6%), reaching an all-time high during August. Despite the outperformance, we still like the company given its profitable business model and defensive qualities. Healthcare company Avantor (+5.3%) also contributed positively, as it works through the unwind of its Covid revenue boost. Medical technology company Boston Scientific (+4.0%) outperformed after positive clinical trial results for its pulse field ablation system (PFA) used in atrial fibrillation. This data should be supportive of US FDA approval of its PFA system in 2024.


Negative contributors this month included WillScot Mobile Mini (-14.5%), the market leader in portable storage units. Second quarter results were slightly disappointing due to temporary factors, but after a follow-up call with the company we think our investment thesis remains intact. Other negative contributors included Japanese media giant Sony (-8.8%) and software company Nice (-10.6%).

Closer to home, the top contributor was Goodman Group (+13.7%), the global leader in industrial real estate. Goodman has an enviable set of property assets, with strong rental growth prospects and additional development opportunities. New Zealand accounting software giant Xero (+2.4%) was another standout and is now up a whopping 76% year to date. Engineering services company Monadelphous (+7.7%) had another strong month on improving fundamentals. Negative contributors included medical devices company ResMed (-24.0%), as quarterly results underwhelmed with margins disappointing analysts' estimates.

Looking ahead, the good news is most global central banks are close to peak or have already completed their interest rate hikes this cycle. We continue to find compelling opportunities that are aligned with our favourite investment themes.

To view Milford's August 2023 Market and Economic Review please see milfordasset.com/insights.

Cumulative Fund Performance (after fees and before tax)



Assumes the growth of \$10,000 invested at the Fund's inception date.

Key Fund Facts

Objective²	To maximise capital growth over the minimum recommended investment timeframe
Description	Primarily invests in international equities, with a moderate allocation to Australasian equities

Minimum recommended investment timeframe	10 years +
Target Allocation	5% Income Assets / 95% Growth Assets
Neutral FX Exposure	24.5%
Net Asset Value (NAV)	\$1,273.8 M
Buy-sell Spread	None - swing pricing applies (See PDS for details)
Inception Date	21 June 2021
Benchmark	Not applicable
Base Fund Fee³	1.15%
Performance Fee	Not applicable
Total Fund Fees⁴	1.15%

Risk Indicator	<div style="display: flex; justify-content: space-between; align-items: center;"> Lower risk 1 2 3 4 5 6 7 Higher risk </div> <div style="display: flex; justify-content: space-between; align-items: center; margin-top: 5px;"> Potentially lower returns Potentially higher returns </div>
-----------------------	--

Aggressive Fund as at 31 August 2023

Investment Performance after fees as at 31 August 2023⁵

Unit Price: \$1.035

	1 Month	3 Months	1 year	3 years (p.a.)	5 years (p.a.)	Since inception (p.a.)
Milford Aggressive Fund (Gross Of Tax)	-2.00%	2.65%	9.22%	-	-	1.73%
After Tax 10.50%	-1.95%	2.61%	8.98%	-	-	1.51%
After Tax 17.50%	-1.91%	2.59%	8.82%	-	-	1.37%
After Tax 28.00%	-1.85%	2.55%	8.58%	-	-	1.15%
Market Index ¹	-0.63%	5.76%	12.85%	-	-	4.34%

Top Security Holdings

Holdings	% of Fund
Meta Platforms	2.97%
Microsoft	2.53%
Arthur J Gallagher	2.43%
Avantor	2.43%
Sony	2.37%
Elevance Health	2.28%
Coca-Cola Europacific Partners	2.27%
HCA Holdings	2.25%
Boston Scientific	2.18%
Aptiv	2.18%

Current Asset Allocation


	Actual Investment Mix	Neutral Investment Mix
Effective Cash [#]	3.90%	5%
New Zealand Fixed Interest	0.11%	0.0%
International Fixed Interest	0.02%	0.0%
New Zealand Equities	5.27%	5%
Australian Equities	19.79%	20%
International Equities	70.91%	70%
Other	0.00%	0.0%

[#] The actual cash held by the Fund is 4.30%. Effective Cash reported above is adjusted to reflect the Fund's notional positions (e.g. derivatives used to increase or reduce market exposure).

Sector Allocation

Allocation	Weight %
Health Care	17.42%
Financials	13.86%
Information Technology	12.76%
Consumer Discretionary	12.53%
Industrials	9.97%
Materials	7.90%
Consumer Staples	6.51%
Communication Services	5.46%
Other Sectors	9.69%
Cash and Other	3.90%

Region Exposure



1. The Fund does not have a performance benchmark, hence a market index has been included for comparison purposes. See the Statement of Investment Policy and Objectives for more details on the market index. The market index is a blend of indices that represent the Fund's neutral asset allocation. Note the Fund's investment strategy is designed to achieve its objective, which may mean that at times, the returns of the market index may not be an appropriate measure. 2. After the base fund fee but before tax and before the performance fee. 3. Where applicable, the Base Fund Fee includes an estimate of non-related underlying fund charges. 4. The Total Fund Fees comprise the Base Fund Fee and any estimated Performance Fee. Please refer to the Product Disclosure Statement for more information as to how these are calculated. 5. Please note past performance is not a guarantee of future returns.

Please refer to the 'Glossary for the Monthly Fact Sheet' at milfordasset.com/fact-sheet-ks for more information about the data published within this document.

Disclaimer: The Milford Fund Fact Sheet has been prepared by Milford Funds Limited. It is based on information believed to be accurate and reliable although no guarantee can be given that this is the case. No reproduction of any material either in part or in full is permitted without prior permission. For more information about the Fund, please refer to the Production Disclosure Statement or the latest Quarterly Fund Update.